Phase II study of cisplatin and 5-fluorouracil (PF) and mitomycin C, vincristine, cisplatin and 5-fluorouracil (MVPF) in patients with metastatic large bowel cancer: An Eastern Cooperative Oncology Group study (EST 1285)

Oncology

Volumn 66, Issue 2, 2004, Pages 118-125

  Pandya, Kishan J ^a   Lefkopoulou, Myrto ^b   Petrelli, Nicholas J ^c   Vaughn, David J ^d   Smith, Thomas J ^e   Harris, Jules E ^f   Haller, Daniel G ^d  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MORRISTOWN MEMORIAL HOSPITAL   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Colorectal cancer; Large bowel cancer; Metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; MITOMYCIN C; VINCRISTINE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; LARGE INTESTINE CANCER; LIVER TOXICITY; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SKIN TOXICITY; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; UROGENITAL TRACT DISEASE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COLONIC NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; PROCARBAZINE; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE; VINCRISTINE;

EID: 2342634323     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077437     Document Type: Article

References (36)

1. Davis HL: Chemotherapy of large bowel cancer. Cancer 1982;50:2638-2646.
2. Ansfield F, Klotz J, Nealon T, et al: A phase III study comparing the clinical utility of four regimens of 5-fluorouracil. A preliminary report. Cancer 1977;39:34-40.
3. Seifert P, Baker L, Reed M, et al: Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975;36:123-138.
4. Crooke ST, Bradner WT: Mitomycin C: A review. Can Treat Rev 1976;3:121-139.
5. Pouillart P, Huong MT, Burgerie E, et al: Sequential administration of two oncostatic drugs: Study of modalities for pharmacodynamic potentiation. Biomedicine 1974;21:471-479.
6. Kovach JS, Moertel CG, Schutt AJ, et al: Phase II study of cis-diamminedichloroplatinum in advanced carcinoma of the large bowel. Can Chemother Rep 1973;57:357-359.
7. Bergerat JP, Barlogie B, Drewinko B: Effects of cis-dichlorodiammine platinum (II) on human colon carcinoma cells in vitro. Can Research 1979;39:1334-1338.
8. Woodman RJ, Sirica AE, Gang M: The enhanced therapeutic effect of cis-platinum (II) diaminodichloride against L1210 leukemia when combined with cyclophosphamide or several other antitumor agents. Chemotherapy 1973;18:169-183.
9. Schabel FM Jr, Trader MW, Laster WR, et al: Cis-dichlorodiammineplatinum (II): Combination chemotherapy and cross-resistance studies with tumors of mice. Can Treat Rep 1979;63:1459-1473.
10. Bergerat J-P, Green C, Drewinko B: Combination chemotherapy in vitro IV: Response of human colon carcinoma cells to combinations using cis-diamminedichloroplatinum. Can Biochem Biophys 1979;3:173-180.
11. Moertel CG, O'Connell MJ, Ritts RE Jr, et al: A controlled evaluation of combined immunotherapy (MER-BCG) and chemotherapy for advanced colorectal cancer; in Ter WD, Windhurst D (eds): Immunotherapy of Cancer: Present Status of Trials of Man. New York, Raven Press, 1978:573-586.
12. Shepard KV, Bitran JD, Sweet DL, et al: Treatment of metastatic colorectal carcinoma with cisplatinum (DDP) and 5-fluorouracil (5-FU). Proceed ASCO 1984;3:147.
13. Einhorn LH, Williams DS, Loehrer PJ: Combination chemotherapy with platinum (P) plus 5-FU in metastatic colorectal carcinoma. Proceed ASCO 1984;3:133.
14. Petrelli N, Madajewicz S, Rustum Y, et al: Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal carcinoma. Cancer Chemother Pharmacol 1989;23:57-60.
15. Pandya KJ, Chang AYC, Asbury RF, et al: Combination chemotherapy for advanced colorectal cancer. A pilot study. Am J Clin Oncol 1986;9:31-34.
16. Pandya KJ: Unpublished data.
17. Oken MM, Creech RM, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
18. Mehta CR, Patel NR, Tsiatis AA: Exact significance testing for ordered categorical data. Biometrics 1984;40:819-825.
19. Cox DR: The analysis of binary data. London: Methuen, 1970.
20. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Nat Cancer Inst 1959;22:719-748.
21. Cox DR: Regression models and life-tables. JR Statist Soc B 1972;34:187-220.
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Statist Ass 1958;53:457-481.
23. O'Connell MJ, Moertel CG, Kvols LK, et al: Clinical trial of cisplatin and intensive course 5-fluorouracil for the treatment of advanced colorectal cancer. Am J Clin Oncol 1986;9:192-195.
24. Dy C, Gil A, Algarra SM, et al: Combination chemotherapy of cisplatin and 5-FU in advanced colorectal carcinoma. Cancer Treat Rep 1986;70:465-468.
25. Whitehead RP, Fleming TR, Macdonald JS, et al: A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin. A Southwest Oncology Group Study. Invest New Drugs 1991;9:345-347.
26. Loehrer PJ Sr, Turner S, Kubilis P, et al: A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: A Hoosier Oncology Group Trial. J Clin Oncol 1988;6:642-648.
27. Labianca R, Pancera G, Cesana B, et al: Cisplatin + 5-fluorouracil versus 5-fluorouracil alone in advanced colorectal cancer: A randomized study. Eur J Cancer Clin Oncol 1988;24:1579-1581.
28. Kemeny N, Israel K, Niedzwiecki D, et al: Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J Clin Oncol 1990;8:313-318.
29. Cantrell JR Jr, Hart RD, Taylor RF, et al: Pilot trial of prolonged continuous-infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer. Cancer Treat Rep 1987;71:615-618.
30. LoRusso P, Pazdur R, Redman BG, et al: Lowdose continuous infusion 5-fluorouracil and cisplatin: Phase II evaluation in advanced colorectal carcinoma. Am J Clin Oncol 1989;12:486-490.
31. Hansen RM, Ryan L, Anderson T, et al: Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 1996;88:668-674.
32. Ross P, Norman A, Cunningham D, et al: A prospective randomized trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol 1997;8:995-1001.
33. Mothe G, Kidani Y, Segignchi M, et al: Oxalito-platinum or L-OHP, a third-generation platinum complex: An experimental and clinical appraisal and preliminary comparison with cisplatinum and carboplatinum. Biomed Pharmacother 1989;43:237-250.
34. Garufi C, Brienza S, Bensmaine MA, et al: Addition of oxaliplatin (L-OHP) to chronomodulated (CM) 5-fluorouracil (5-FU) and folinic acid (FA) for reversal of acquired chemoresistance in patients with advanced colorectal cancer (ACC). Proc Am Soc Clin Oncol 1995; 14:192 (abstr 446).
35. Fink D, Nebel S, Aebi S, et al: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 1996;56:4881-4886.
36. Misset JL, Bleiberg H, Sutherland W, et al: Oxaliplatin clinical activity: A review. Crit Rev Oncology-Hematology 2000;35:75-93.